DMAAFinancial Services · Shell CompaniesDMAA Stock Forecast: Drugs Made In America Acquisition Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 1 Aug 2026 — in the upper half.
DMAA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Drugs Made In America Acquisition Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Growth (23): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Drugs Made In America Acquisition Corp. — and when they’d sell — is the membership.
DMAA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DMAA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DMAA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Drugs Made In America Acquisition Corp. (DMAA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 53.5×
- Price / sales
- —
- Price / book
- 1.5×
- EV / EBITDA
- −128.3×
Cheaper than 14% of US stocks
Cheaper than 55% of US stocks
Cheaper than 97% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 57.1%
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 79% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 2.6%
- Return on assets
- 2.5%
- Dividend yield
- —
Higher than 49% of US stocks
Higher than 62% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
DMAA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| DMAADrugs Made In America Acquisition Corp. | $260.0M | 50 |
| TRGSTRG Latin America Acquisitions Corp. | $261.7M | 15 |
| NTWONewbury Street II Acquisition Corp. | $258.3M | 50 |
| VNMEVendome Acquisition Corp. I | $263.9M | 35 |
| OACCOaktree Acquisition Corp. III Life Sciences | $264.0M | 54 |
| RACRithm Acquisition Corp. | $255.1M | 51 |
| SCIISC II Acquisition Corp. | $251.7M | 13 |
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DMAA appears on the weeks it earns a place.
Frequently asked questions about DMAA stock
How does Ticker Nerd's model rank DMAA?
As at 1 Aug 2026, Drugs Made In America Acquisition Corp. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
What is the DMAA stock forecast for 2030?
No analyst covering Drugs Made In America Acquisition Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DMAA are extrapolating price history, which says nothing about the business.
How has DMAA stock performed over the past year?
Drugs Made In America Acquisition Corp. returned +4.3% over the 12 months to 31 July 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Drugs Made In America Acquisition Corp. do?
Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) established in 2024 and headquartered in Fort Lauderdale, Florida.
About Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) established in 2024 and headquartered in Fort Lauderdale, Florida. The company’s primary purpose is to facilitate a merger, share exchange, asset acquisition, or similar business combination with one or more businesses in the U.S. pharmaceutical sector. Emphasizing the importance of domestic pharmaceutical manufacturing, the firm actively seeks to identify and acquire revenue-generating businesses that can serve as the foundation for an "end-to-end" platform focused on producing drugs within the United States. By doing so, it aims to contribute to job creation, strengthen national security, and ensure a reliable domestic supply of affordable, high-quality medications. The company is guided by an experienced management and advisory team, including prominent industry leaders, leveraging deep sector relationships and expertise to achieve its objectives. In the broader financial market, Drugs Made In America Acquisition Corp. represents the growing trend of SPACs targeting healthcare innovation and supply chain resilience, positioning itself as a strategic player in the future landscape of U.S. pharmaceutical manufacturing.
CEO Ms. Lynn Stockwell · United States · https://dmaacorp.com